Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
<sup>18</sup>F-FDG PET/CT Imaging In Oncology
361
Zitationen
3
Autoren
2011
Jahr
Abstract
Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of management is changed. This review provides guidance for oncologists/radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.117 Zit.
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 · 28.449 Zit.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.367 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.721 Zit.
Image processing with ImageJ
2004 · 11.903 Zit.